Skip to content
Peptidepedia

AOD-9604 Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

The clinical development of AOD-9604 produced a mixed evidence base: strong preclinical results that did not translate into convincing human efficacy data.

Preclinical studies (late 1990s to early 2000s): Animal studies conducted at Monash University demonstrated that chronic administration of AOD-9604 to obese mice produced significant reductions in body weight gain, increased in vivo fat oxidation, and elevated plasma glycerol levels (a marker of lipolysis). These effects were mediated through the beta-3 adrenergic receptor pathway and were absent in beta-3 AR knockout animals.

Phase I/IIa trials (2001 to 2004): Early human studies established safety and tolerability. A 12-week randomized, double-blind, placebo-controlled trial of approximately 300 obese adults demonstrated that subjects receiving 1 mg/day oral AOD-9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group. These results were statistically significant and encouraged further development.

Phase IIb OPTIONS trial (2006 to 2007) — the definitive result: The larger and more rigorous 24-week Phase IIb trial enrolled 536 obese subjects randomized to receive 0.25, 0.5, or 1 mg/day oral AOD-9604 or placebo. The trial failed to meet its primary endpoint: none of the treatment arms demonstrated statistically significant weight loss compared to placebo. Metabolic Pharmaceuticals terminated development of AOD-9604 as an anti-obesity drug in March 2007. This Phase IIb failure is the most important clinical data point for AOD-9604 — a well-powered trial that directly contradicted the earlier, smaller Phase IIa result.

Safety review (2013): A comprehensive analysis published by Stier et al. pooled safety data from all six clinical trials (893 participants). AOD-9604 displayed a tolerability profile indistinguishable from placebo, with no serious adverse events attributed to the peptide, no impact on IGF-1 or glucose metabolism, and no detectable antibody formation.

Cartilage research (2015): A rabbit osteoarthritis model demonstrated that intra-articular AOD-9604, alone or combined with hyaluronic acid, improved cartilage regeneration and reduced joint degradation. These findings remain preclinical.

The honest assessment: AOD-9604's preclinical promise did not survive rigorous clinical testing. While the peptide appears safe, the evidence does not support it as an effective anti-obesity treatment at the doses studied.

Frequently Asked Questions

Early 12-week clinical trials showed modest weight loss (2.6 kg vs. 0.8 kg placebo), but the larger 24-week Phase IIb trial with 536 subjects failed to demonstrate statistically significant fat loss. Drug development was abandoned in 2007. Current evidence does not support AOD-9604 as an effective standalone weight-loss treatment.

Across six clinical trials involving 893 participants, AOD-9604 displayed a safety profile indistinguishable from placebo. The most commonly reported effects were mild injection-site reactions and occasional headaches. Unlike full HGH, it did not elevate IGF-1, impair glucose tolerance, or trigger antibody formation.

Semaglutide is far more effective. Clinical trials show semaglutide produces 13 to 20% body weight reduction at maintenance doses, while AOD-9604 failed to produce statistically significant weight loss in its pivotal trial. Semaglutide is also FDA-approved, whereas AOD-9604 is not approved for any therapeutic use.

AOD-9604 is not approved as a drug by any major regulatory agency. In the United States, the FDA declined to include it on the 503A bulk drug substances list for compounding in December 2024. It is sold as a research chemical and is prohibited in competitive sport by WADA.

Clinical trials used oral doses of 250 to 1,000 mcg per day. In community use, subcutaneous doses of 300 to 500 mcg daily are most common, administered in a fasted state. These dosage protocols are not FDA-approved and are based on limited clinical and anecdotal data.

Based on clinical trial data, measurable changes in body composition were observed over 12 to 24 weeks of daily use. However, results were modest and inconsistent across studies. Most community reports suggest 8 to 12 weeks as a minimum evaluation period.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
  2. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
  3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.
  4. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77.
  5. Kok P, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. J Clin Endocrinol Metab. 2001;86(2):455-459.
  6. Obesity Pharmacotherapy: Current Perspectives and Future Directions. PMC. 2013.
  7. Kwon DR, et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432.
  8. WADA Statement on Substance AOD-9604. World Anti-Doping Agency.
  9. FDA Pharmacy Compounding Advisory Committee Meeting, December 4, 2024.
  10. PubChem Compound Summary: AOD-9604. CID 71300630.
←Read the full AOD-9604 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”